Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
| 0.015 | |
| 0.016 | |
| - | |
| 0.016 | |
| 0.015 | |
| 0.015-0.047 | |
| 13 404 K | |
| 894 M | |
| 7 458 K | |
| -0.03 | |
| 1.458 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional Investors NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Dia...
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional Investors NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Dia...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
